Efficacy of Radiotherapy Combined with EGFR-TKI in the Treatment of EGFR/TP53 Co-Mutated NSCLC

被引：0
|
作者：
Zeng, S. [1 ]
Wang, L. L. [1 ]
Tao, D. [1 ]
Zhou, W. [1 ]
Wu, Y. [2 ]
机构：
[1] Chongqing Univ Canc Hosp, Dept Radiat Oncol, Chongqing, Peoples R China
[2] Chongqing Univ, Coll Med, Chongqing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2189
引用
收藏
页码：E86 / E86
页数：1
相关论文
共 50 条
  • [21] The efficacy of chemotherapy in the advanced NSCLC patients who failed with the treatment of EGFR-TKI
    Zhou, S.
    Ren, S.
    Zhang, L.
    Sun, H.
    Zhou, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] CYTOPLASMIC ERBEXPRESSION PREDICTS POORLY EFFICACY AND SURVIVAL OF EGFR-TKI IN EGFR MUTANT NSCLC
    Wang, Zhijie
    Li, Zhenxiang
    Bai, Hua
    Wang, Jie
    Zhao, Jun
    Wu, Meina
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S354 - S354
  • [23] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Zhuchen Yu
    Fei Xu
    Juntao Zou
    European Journal of Clinical Pharmacology, 2024, 80 : 505 - 517
  • [24] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Yu, Zhuchen
    Xu, Fei
    Zou, Juntao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (04) : 505 - 517
  • [25] Update Phase II Results of Early Primary Tumor Stereotactic Body Radiotherapy Combined with First-Line EGFR-TKI in Advanced EGFR Mutated NSCLC
    Lv, D.
    Xu, H.
    Meng, Y.
    Wang, W.
    Wu, X.
    Kong, F.
    Yang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S395 - S396
  • [26] NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI
    Facchinetti, Francesco
    Tiseo, Marcello
    Gnetti, Letizia
    Silini, Enrico Maria
    Ardizzoni, Andrea
    LUNG CANCER, 2013, 82 (01) : 177 - 178
  • [27] Efficacy and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Minemura, H.
    Sugiyama, T.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Minato, K.
    Kaburagi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S943 - S943
  • [28] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Ren, Shengxiang
    Li, Wei
    Li, Aiwu
    Chen, Xiaoxia
    Gao, Guanghui
    He, Yayi
    Li, Xuefei
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
  • [29] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kei Kunimasa
    Kazumi Nishino
    Yoshiharu Sato
    Masahide Mori
    Shoichi Ihara
    Hidekazu Suzuki
    Izumi Nagatomo
    Toru Kumagai
    Toshitaka Morishima
    Fumio Imamura
    Scientific Reports, 12
  • [30] ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
    Wang, Zhijie
    Li, Zhenxiang
    Ding, Xiaosheng
    Shen, Zhirong
    Liu, Zhentao
    An, Tongtong
    Duan, Jianchun
    Zhong, Jia
    Wu, Meina
    Zhao, Jun
    Zhuo, Minglei
    Wang, Yuyan
    Wang, Shuhang
    Sun, Yu
    Bai, Hua
    Wang, Jie
    SCIENTIFIC REPORTS, 2015, 5
12345